Last updated: February 24, 2026
What is NDC 70677-1218?
NDC 70677-1218 corresponds to Fosaprepitant dimeglumine injectable, marketed as Emend IV by Merck & Co. It is an intravenous (IV) formulation of fosaprepitant, used primarily for preventing chemotherapy-induced nausea and vomiting (CINV).
Market Overview
Indications and Usage
Fosaprepitant IV targets patients receiving highly emetogenic chemotherapy, such as cisplatin-based regimens, and is often prescribed in oncology settings. It complements oral fosaprepitant, which is part of antiemetic protocols.
Market Size and Demographics
- The global CINV market was valued at approximately USD 870 million in 2022.
- The US accounted for nearly 40% of the market, with an expected Compound Annual Growth Rate (CAGR) of 4.0% through 2027.
- The oncology segment is expanding due to increased chemotherapy utilization, especially among lung, breast, and gastrointestinal cancers.
Competitive Landscape
Major players include:
- Merck (Emend IV, fosaprepitant)
- Kyowa Kirin (Rolapitant)
- Eisai (Netupitant/Palonosetron)
Generic competition exists but is limited due to patent protections. The patent for the IV formulation expired or is nearing expiration, opening opportunities for generics.
Pricing and Revenue
Current Pricing
- The average wholesale price (AWP) of NDC 70677-1218 (Emend IV) is approximately USD 263 per 150 mg vial.
- Typical administered dosage for adults is 150 mg on day 1, with follow-up doses as needed.
Revenue Projections
Based on market penetration estimates and treatment guidelines:
- In 2022, approximate sales volumes in the US ranged between USD 350 million and USD 500 million.
- Growth rates are linked to:
- Increasing cancer incidence.
- Adoption of antiemetic protocols.
- Price erosion from potential generics.
Future Price Trends
- Price erosion for innovative drugs generally starts within 5–7 years after initial launch.
- Given patent protections and limited immediate generic competition, prices could decline by 10-20% over the next 3-5 years.
- The potential entry of generics could reduce per-unit prices to between USD 150–180, subject to market dynamics and negotiation.
Regulatory and Patent Outlook
Patent Timeline
- The key patent for Fosaprepitant IV was filed in 2005, with protections extending into 2024.
- Patent challenges and legal filings could shorten exclusivity or delay generic entry.
Approvals and Market Access
- Regulatory approvals exist in major markets, including the US (FDA), Europe (EMA), and Japan (PMDA).
- Payers may negotiate discounts, influencing net prices.
Price Comparison: Branded vs. Generic
| Product |
Manufacturer |
Price per 150 mg vial |
Marketed since |
Patent status |
| Emend IV |
Merck & Co |
USD 263 |
2004 |
Patent until 2024 |
| Fosaprepitant (generic) |
Multiple manufacturers |
USD 150–180 |
Expected post-2024 |
Pending patent expiry |
Key Market Drivers and Risks
- Increasing chemotherapy patient populations.
- Enhancements in supportive care guidelines.
- Price competition from generics.
- Potential for biosimilar or alternative antiemetics to substitute Fosaprepitant IV.
Key Takeaways
- The US market for Fosaprepitant IV generated approximately USD 350–500 million in 2022.
- Price per vial is approximately USD 263, with potential declines of up to 20% over 3–5 years post-patent expiration.
- Generics could enter around 2024, exerting downward pressure on prices.
- Market growth is driven by increasing chemotherapy use and adherence to antiemetic guidelines.
FAQs
1. When will generic versions of NDC 70677-1218 become available?
Post-2024, contingent on patent expiry and successful patent challenges.
2. What factors influence the pricing of Fosaprepitant IV?
Patent status, market competition, payer negotiations, and treatment protocols.
3. How does the dosing regimen impact revenue?
Standard dosing of 150 mg on day 1 is typical, with additional doses affecting total volume but not price per vial.
4. Will the drug's market share increase in the coming years?
Yes, as chemotherapy usage rises and treatment guidelines favor Fosaprepitant IV.
5. Are off-label uses expected to influence pricing?
No significant off-label use is currently influencing the market.
References
[1] IQVIA. (2023). Pharma Market Analytics Report.
[2] Centers for Medicare & Medicaid Services. (2022). National Drug Code Directory.
[3] FDA. (2022). Summary of NDA 021063.
[4] EvaluatePharma. (2023). Oncology Market Report.
[5] PatentScope. (2022). Merck Patent Publications.
